13:05 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting PIEZO1 for nerve damage

DISEASE CATEGORY: Neurology INDICATION: Nerve damage Fruit fly and mouse studies suggest inhibiting PIEZO1 could help treat nerve damage. In two Drosophila models of sensory nerve injury and one Drosophila model of motor nerve injury,...
15:20 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Pancreatitis Mouse studies suggest PIEZO1 inhibition could help treat pancreatitis. In a mouse model of pressure-induced acute pancreatitis, pancreatic acinar cell-specific knockout of PIEZO1 or the PIEZO1 inhibitor AT-300 decreased histological disease scores and...
20:17 , Mar 24, 2017 |  BC Week In Review  |  Clinical News

HT-100 regulatory update

FDA granted Akashi clearance to resume clinical development of Duchenne muscular dystrophy (DMD) candidate HT-100. The company said it plans to start a new Phase IIa trial “as quickly as possible.” In January 2016, Akashi...
22:31 , Mar 22, 2017 |  BC Extra  |  Clinical News

Akashi restarting development of DMD candidate

Akashi Therapeutics Inc. (Cambridge, Mass.) said FDA granted the company clearance to resume clinical development of Duchenne muscular dystrophy candidate HT-100 . The company said it intends to start a new Phase IIa trial “as...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Halofuginone: Phase Ib/IIa halted

Akashi said that a patient treated with HT-100 in the open-label, U.S. Phase Ib/IIa HALO trial in boys and young men with ambulatory or non-ambulatory DMD has died. In late January, Akashi suspended dosing and...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Halofuginone: Phase Ib/IIa suspended enrollment

Akashi suspended dosing and enrollment in all cohorts of the open-label, U.S. Phase Ib/IIa HALO trial in boys and young men with ambulatory or non-ambulatory DMD after 1 patient receiving once-daily 60 ug/kg HT-100, the...
01:47 , Jan 27, 2016 |  BC Extra  |  Clinical News

Akashi halts DMD program

Akashi Therapeutics Inc. (Cambridge, Mass.) said it suspended dosing and enrollment of all clinical studies of HT-100 to treat Duchenne muscular dystrophy after a patient experienced undisclosed "serious, life-threatening health issues." The patient had been...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

Akashi Therapeutics, Gruenenthal deal

The companies partnered exclusively to develop and commercialize Akashi’s HT-100 . Gruenenthal will be responsible for development following Phase II testing and also will develop Akashi’s U.S. commercial infrastructure. Akashi granted Gruenenthal rights to commercialize...
02:22 , Jan 9, 2016 |  BC Extra  |  Company News

Patient-funded Akashi partners DMD compound

Akashi Therapeutics Inc. (Cambridge, Mass.) and Gruenenthal Group (Aachen, Germany) partnered to develop Akashi's HT-100 for Duchenne muscular dystrophy (DMD). The compound, an oral delayed-release formulation of the collagen type I ( COL1 ) inhibitor...
07:00 , Oct 8, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Eukaryotic translation initiation factor 2 α kinase 4 (EIF2AK4; GCN2)

Autoimmune disease INDICATION: Lupus Cell culture and mouse studies suggest promoting EIF2AK4 activity could help treat lupus. In a mouse model of lupus, macrophage-specific knockout of EIF2AK4 increased numbers of spleen cells, spleen levels of...